ClinicalTrials.gg
Status unknownNCT05096065Updated Mar 22, 2022

Study to Evaluate the Pharmacodynamics and Efficacy of Leuprolide Tablets (Ovarest®) in Women With Endometriosis

A Phase 2 interventional study of Leuprolide Oral Tablet - 120 mg - QD- Treatment A and Leuprolide Oral Tablet - 80 mg - QD - Treatment B in Endometriosis, sponsored by Enteris BioPharma Inc.. Status unknown at 4 sites in United States. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2022-03-22.

Sponsored by Enteris BioPharma Inc. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 169 studies in Endometriosis with a site in United States — 38 open to participants now, 48 under way, 5 of them phase 3. Endometriosis · United States.

Planned enrollment
103rd of 131
16 · median 60
Started
2022
with 14 others
Phase 2
39 of 169
1 open now
Registered
114th of 169
by date

Among the 169 studies in Endometriosis with a site in United States, this one is the 103rd largest by planned enrollment of the 131 interventional ones that give a count, is one of 15 that started in 2022, is one of 39 in phase 2, and was the 114th registered.

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

Browse Endometriosis studies →

Open to participants now

38 of the 169 studies in Endometriosis with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 49 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 169 studies in Endometriosis with a site in United States, or all of them as a file.
02

Study summary

The pharmacodynamic endpoint of percentage of subjects with suppressed estradiol level (less than 20 pg/mL) on cycle day 29 is the primary endpoint of the study.

Read the detailed description

Objectives of this study:

  1. To determine efficacy and pharmacodynamic effects of various dosing regimens of Ovarest® (within the 60-mg - 120 mg daily dosing range) in women with endometriosis.
  2. To determine a minimally effective daily dosing regimen of Ovarest® with pharmacodynamic effects at least comparable to the historical data for marketed Lupron Depot formulations and for GnRH antagonists indicated for the treatment of endometriosis.
  3. To evaluate safety and tolerability of the long-term administration of leuprolide within the targeted daily dosing range in women with endometriosis.

The most important goal of this study is to provide adequate dose-response data for the suppression of estradiol (E2) levels below the menopausal threshold of 20 pg/mL. Results of this study in conjunction of Enteris proprietary PK data will support further development of Leuprolide Acetate Oral Tablet for the treatment of reproductive disorders, particularly endometriosis. Another reason for this trial is to support a comparative evaluation of the PD effects across the QD and BID regimens delivering the same overall dose of Ovarest

03

Conditions studied

  • Endometriosis

Browse trials for

Keywords

  • Leuprolide oral tablets
  • Endometriosis
  • pharmacodynamic
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women diagnosed with endometriosis and having pelvic pain, both treatment naive or previously treated with GnRH agonists or antagonists with improvement
  2. Premenopausal females in general good health, including absence of current COVID infection (positive test or presence of symptoms), aged 18 to 49 years
  3. ≥18 and ≤35 kg/m2, and weight ≥110 lb. (≈50 kg).
  4. A documented estradiol level ≥ 40 pg/mL at screening or on retest
  5. Regular menstrual cycles with a usual length ranging from 21 days to 35 days. If subject has recently used hormonal , historical data prior to use will be used to determine qualification and must also meet this criterion.
  6. If of and sexually active with a risk of pregnancy, willing to use acceptable methods of contraception (Note: acceptable methods of contraception are specified in Section 8.1)
  7. Willing to refrain from excessive use of alcohol during the entire study and willing to refrain from use of alcohol 24 hours prior to any PK blood draw taken during the study
  8. Willing to refrain from the use of any hormone-containing or hormone-altering substances during the study.
  9. Willing and able to adhere to medication schedule and to utilize the AiCure medication adherence monitoring platform correctly with the administration of each dose of medication throughout the duration of the 3 treatment cycles comprising this study
  10. Willing and capable to give to participate in study

Exclusion criteria

Exclusion Criteria:

Subjects to whom any of the following applies will be excluded from the study:

  1. to GnRH, GnRH agonist analogs, similar nonapeptides, or any of the in LUPRON DEPOT. Note: This is a from the Lupron Depot label.
  2. Undiagnosed abnormal vaginal bleeding. Note: This is a contraindication from the Lupron Depot label.
  3. Known or suspected pregnancy, or subjects who are considering becoming pregnant prior to the conclusion of this study. Note: LUPRON DEPOT is contraindicated in women who are or may become pregnant while receiving the drug. LUPRON DEPOT may cause fetal harm when administered to a pregnant woman.... If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
  4. Breastfeeding or within 2 months after stopping breastfeeding (relative to the screening visit). Note: Use of LUPRON DEPOT is contraindicated in women who are breastfeeding.
  5. Thrombophlebitis, thromboembolic disorders, cerebral apoplexy, or a past history of these conditions. Note: Per the LUPRON DEPOT label, a possible coadministration of norethindrone acetate is contraindicated in women with thrombophlebitis, thromboembolic disorders, cerebral apoplexy, or a past history of these conditions.
  6. Markedly impaired liver function or liver disease. Note: Per the LUPRON DEPOT label, a possible coadministration of norethindrone acetate is contraindicated in women with markedly impaired liver function or liver disease.
  7. Known or suspected carcinoma of the breast. Note: Per the LUPRON DEPOT label, a possible coadministration of norethindrone acetate is contraindicated in women with known or suspected carcinoma of the breast.
  8. Status postpartum or postabortion within a period of 2 months prior to the screening visit
  9. History of significant alcohol or drug abuse within one year prior to the screening visit
  10. vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mm Hg, diastolic blood pressure lower than 50 or over 90 mm Hg, or heart rate less than 50 or over 100 bpm) at screening (following recheck after five minutes at rest)
  11. Any clinically significant history or presence of neurologic, endocrinologic, pulmonary, hematologic, immunologic, or metabolic disease
  12. History of severe respiratory depression or pulmonary insufficiency
  13. Diabetes mellitus requiring insulin
  14. History of headaches with focal neurological symptoms
  15. Uncontrolled thyroid disorder
  16. Sickle cell anemia
  17. Current or history of clinically significant depression in the last year
  18. Known disturbance of lipid metabolism
  19. Hepatic adenoma or carcinoma
  20. Known or suspected endometrial carcinoma or estrogen-dependent neoplasia
  21. Clinically significant history or presence of any gastrointestinal pathology (e.g., chronic diarrhea, inflammatory bowel diseases, history of cholecystectomy), unresolved gastrointestinal symptoms (e.g., diarrhea, vomiting) or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug
  22. Difficulty in swallowing study medication
  23. Any food allergy, intolerance, restriction or special diet that, in the opinion of the Investigator, could contraindicate the subject's participation in this study
  24. Positive test for , , or (HIV) at screening
  25. Administration of any drug and/or experimental device within 30 days prior to the screening visit
  26. Administration of any biologics within 30 days prior to the screening visit. Note: The Covid-19 vaccine is not included in this prohibition.
  27. Clinically significant finding on the suggesting participation in the study could pose a risk to the subject
  28. A depot injection or an implant of any drug within 1 month prior to the screening visit
  29. Use of oral or other sex hormones within 1 month prior to the screening visit. Note: A 1-month drug holiday period is mandatory for potential subjects receiving GnRH agonists and GnRH antagonists.
  30. Any clinically significant physical or gynecological abnormality at the screening visit
  31. Any clinically significant abnormal laboratory test result at the screening visit
  32. \<11.5 g/dL and/or hematocrit \<32%
  33. Use of over-the-counter products containing any substances which could have the propensity to impact either estradiol or gonadotropin level
  34. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the first dosing
  35. History of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors
  36. Significant risk factors for decreased bone mineral content and/or bone mass, such as family history (in a first degree relative) of osteoporosis, personal history of chronic use of corticosteroids or anticonvulsants
  37. Participation in another drug research within 1 month prior to screening
  38. Deemed by the Investigator to have questionable ability to comply with the study protocol, including inadequate adherence to both dosing and use of the AiCure medication adherence monitoring platform during the Run-in Period or during the three Treatment Cycles
  39. Current use of any prescription medication known to cause delayed gastric emptying (e.g. glucagon-like peptide-1 receptor agonists)
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Treatment A: Leuprolide Oral Tablet, 120 mg QD

    Leuprolide Oral Tablet (Ovarest), 120 mg (2 x 60 mg tablets), administered once daily (QD), for up to 35 consecutive days with food-intake restrictions.

    Drug: Leuprolide Oral Tablet - 120 mg - QD- Treatment A

  • Experimental
    Treatment B: Leuprolide Oral Tablet, 80 mg QD

    Leuprolide Oral Tablet (Ovarest), 80 mg (2 x 40 mg tablets), administered once daily (QD) for up to 35 consecutive days with food-intake restrictions.

    Drug: Leuprolide Oral Tablet - 80 mg - QD - Treatment B

  • Experimental
    Treatment C: Leuprolide Oral Tablet, 60 mg QD

    Leuprolide Oral Tablet (Ovarest), 60 mg, administered once daily (QD) for up to 29 consecutive days with food-intake restrictions.

    Drug: Leuprolide Oral Tablet - 60 mg - QD - Treatment C

  • Experimental
    Treatment D: Leuprolide Oral Tablet, 60 mg BID

    Leuprolide Oral Tablet (Ovarest), 60 mg, administered twice daily (BID), 12 hours apart for up to 35 consecutive days with food-intake restrictions.

    Drug: Leuprolide Oral Tablet - 60 mg - BID - Treatment D

  • Experimental
    Treatment E:Leuprolide Oral Tablet (Ovarest), 40 mg BID

    Leuprolide Oral Tablet (Ovarest), 40 mg, administered twice daily (BID), 12 hours apart for up to 29 consecutive days with food-intake restrictions.

    Drug: Leuprolide Oral Tablet - 40 mg - BID - Treatment E

Interventions

  • DrugLeuprolide Oral Tablet - 120 mg - QD- Treatment A

    If the subject during Treatment "A" meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the First Treatment Cycle), in the Second Treatment Cycle, she will be assigned Treatment "B" - 80 mg (2 x 40 mg tablets) (QD), with food-intake restrictions. If the subject during Treatment "A" fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the First Treatment Cycle), then she will be switched to the Second Treatment Cycle with Treatment "D" - 60 mg (BID) with food intake restrictions.

    Also known as: Ovarest® 60 mg

  • DrugLeuprolide Oral Tablet - 80 mg - QD - Treatment B

    If the subject on Treatment "B" meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment "C" - 60 mg (QD) with food-intake restrictions. If the subject on Treatment "B" does not meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment "E" - 40 mg (BID) with food intake restrictions.

    Also known as: Ovarest® 40 mg

  • DrugLeuprolide Oral Tablet - 60 mg - QD - Treatment C

    For up to 29 consecutive days with food-intake restrictions

    Also known as: Ovarest® 60 mg

  • DrugLeuprolide Oral Tablet - 60 mg - BID - Treatment D

    If the subject on Treatment "D" fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), she will be discontinued from the study following completion of the Second Treatment Cycle. If the subject during Treatment "D" meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of her Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment "E" - 40 mg (BID) with food intake restrictions.

    Also known as: Ovarest® 60 mg

  • DrugLeuprolide Oral Tablet - 40 mg - BID - Treatment E

    For up to 29 consecutive days with food-intake restrictions

    Also known as: Ovarest® 40 mg

06

What researchers measure

Primary outcomes

  1. Adequacy of suppression of estradiol (E2) as assessed by the subject incidence of estradiol level below 20 pg/mL

    The primary PD metric - suppression of E2 level (E2 \<20 pg/mL) - will be assessed at each on-treatment evaluation timepoint. E2 below 20 pg/mL at Day 29 is a primary endpoint for a given Treatment Cycle.

    Time frame: Treatment cycle: Day 29

Secondary outcomes

  1. Suppression of ovulation (as evidenced by progesterone levels <3 ng/mL)

    It will be evaluated with Treatment Cycle Day 22 and Treatment Cycle Day 29 (separately and combined) positioned as most important timepoints for this analyte.

    Time frame: Treatment cycle: Day 22 and 29

  2. Number of vaginal (menstrual) bleeding days

    The onset of menstrual period is defined as at least three consecutive bleeding/spotting days during the 14-day postdosing period.

    Time frame: 28 days of therapy and 14 days post study follow up

  3. Composite Pelvic Signs and Symptoms (CPSS) scores

    CPSS scores (composite and for the individual items) and changes from the pre-dosing baseline will be summarized by treatment received. CPSSS values are derived from the Biberoglu and Behrman scale, with 5 components addressing dysmenorrhea (0-none and 3-severe), dyspareunia (0-none and 3-severe), non-menstrual pelvic pain (0-none and 3-severe), pelvic tenderness (0-none and 3-severe), and pelvic induration (0-none and 3-severe). In composite score (total symptom and sign severity score) 0 being none and 11-15 being very severe.

    Time frame: Treatment day 29

  4. (Pre-dose leuprolide level) Subject incidence of Leuprolide below detectable level

    The summaries will be provided for each PK evaluation timepoint and across the entire treatment cycle

    Time frame: Treatment Cycle: Days 1, 8, 15, 22 and 29 days

  5. Luteinizing hormone (LH) levels

    Serum concentration measured immediately prior to dosing

    Time frame: Treatment days: 1,8, 15, 22 and 29; Post dosing day 14

  6. Follicle Stimulating Hormone (FSH) levels

    Serum concentration measured immediately prior to dosing

    Time frame: Treatment days: 1,8, 15, 22 and 29; Post dosing day 14

07

Study locations

4 of 4 sites recruiting
  • Physician Care Clinical Research, LLC
    Sarasota, Florida 34239, United States
    Recruiting
  • Complete Healthcare for Women
    Columbus, Ohio 43231, United States
    Recruiting
  • Tidewater Clinical Research
    Norfolk, Virginia 23502, United States
    Recruiting
  • Seattle Clinical Research Center
    Seattle, Washington 98105, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for May 2022, 2 months after the start.

Of 44 phase 2 interventional studies under Endometriosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 37. This study's planned 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2021
First posted
Oct 27, 2021
StartActual
Mar 18, 2022
Primary completionEst.
May 2022
CompletionEst.
May 2022
Last update
Mar 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05096065
Lead sponsor
Enteris BioPharma Inc.
Collaborators
Parexel, Syneos Health
Responsible party
Sponsor
First posted
Oct 27, 2021
Start date
Mar 18, 2022
Primary completion
May 2022 (estimated)
Completion
May 2022 (estimated)
Last update
Mar 22, 2022

Study contacts

Gary A. Shangold, M.D.
Contact
gshangold@enterisbiopharma.com
862-261-9113
Sreeja Polpully Variam, M. Pharma
Contact
svariam@enterisbiopharma.com
9734533523
Gary A. Shangold, M.D.
study chair · Enteris BioPharma Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion